Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study

Nicola P. Klein, Remon Abu-Elyazeed, Michael Povey, Mercedes Macias Parra, Javier Diez-Domingo, Anitta Ahonen, Tiina Korhonen, Juan Carlos Tinoco, Leonard Weiner, Gary S. Marshall, Peter E. Silas, Kwabena O. Sarpong, Keith P. Ramsey, John A. Fling, David Speicher, Maribel Campos, Iona Munjal, Christopher Peltier, Timo Vesikari, Carmen BaccariniAdrian Caplanusi, Paul Gillard, Stephane Carryn, Ouzama Henry

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study'. Together they form a unique fingerprint.

Medicine & Life Sciences